VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways

被引:33
作者
del Rio, Carmen [1 ,2 ,3 ]
Cantarero, Irene [1 ,2 ,3 ]
Palomares, Belen [1 ,2 ,3 ]
Gomez-Canas, Maria [4 ,5 ,6 ]
Fernandez-Ruiz, Javier [4 ,5 ,6 ]
Pavicic, Carolina [7 ]
Garcia-Martin, Adela [8 ]
Luz Bellido, Maria [8 ,9 ]
Ortega-Castro, Rafaela [1 ,2 ,3 ]
Perez-Sanchez, Carlos [1 ,2 ,3 ]
Lopez-Pedrera, Chary [1 ,2 ,3 ]
Appendino, Giovanni [10 ]
Calzado, Marco A. [1 ,2 ,3 ]
Munoz, Eduardo [1 ,2 ,3 ]
机构
[1] Univ Cordoba, Maimonides Biomed Res Inst Cordoba, Avda Menendez Pidal S-N, E-14004 Cordoba, Spain
[2] Univ Cordoba, Dept Cellular Biol Physiol & Immunol, Cordoba, Spain
[3] Reina Sofia Univ Hosp, Cordoba, Spain
[4] Univ Complutense, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Invest Neuroquim, Madrid, Spain
[5] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
[6] Inst Ramon y Cajal Invest Sanitaria IRYCIS, Madrid, Spain
[7] Innohlth Grp, Madrid, Spain
[8] Vivacell Biotechnol, Cordoba, Spain
[9] Emerald Hlth Pharmaceut, San Diego, CA USA
[10] Univ Piemonte Orientale, Dipartimento Sci Farmaco, Novara, Italy
关键词
SYSTEMIC-SCLEROSIS; CONCISE GUIDE; TRANSDERMAL DELIVERY; INDUCED SCLERODERMA; IN-VIVO; AGONISTS; AUTOANTIBODIES; CANNABINOIDS; MODEL; FIBROBLASTS;
D O I
10.1111/bph.14450
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
BACKGROUND AND PURPOSE The endocannabinoid system and PPAR gamma are important targets for the development of novel compounds against fibrotic diseases such as systemic sclerosis (SSc), also called scleroderma. The aim of this study was to characterize VCE-004.3, a novel cannabidiol derivative, and study its anti-inflammatory and anti-fibrotic activities. EXPERIMENTAL APPROACH The binding of VCE-004.3 to CB1 and CB2 receptors and PPAR gamma and its effect on their functional activities were studied in vitro and in silico. Anti-fibrotic effects of VCE-004.3 were investigated in NIH-3T3 fibroblasts and human dermal fibroblasts. To assess its anti-inflammatory and anti-fibrotic efficacy in vivo, we used two complementary models of bleomycin-induced fibrosis. Its effect on ERK1/2 phosphorylation induced by IgG from SSc patients and PDGF was also investigated. KEY RESULTS VCE-004.3 bound to and activated PPAR gamma and CB2 receptors and antagonized CB1 receptors. VCE-004.3 bound to an alternative site at the PPAR gamma ligand binding pocket. VCE-004.3 inhibited collagen gene transcription and synthesis and prevented TGF beta-induced fibroblast migration and differentiation to myofibroblasts. It prevented skin fibrosis, myofibroblast differentiation and ERK1/2 phosphorylation in bleomycin-induced skin fibrosis. Furthermore, it reduced mast cell degranulation, macrophage activation, T-lymphocyte infiltration, and the expression of inflammatory and profibrotic factors. Topical application of VCE-004.3 also alleviated skin fibrosis. Finally, VCE-004.3 inhibited PDGF-BB- and SSc IgG-induced ERK1/2 activation in fibroblasts. CONCLUSIONS AND IMPLICATIONS VCE-004.3 is a novel semisynthetic cannabidiol derivative that behaves as a dual PPAR gamma/CB2 agonist and CB1 receptor modulator that could be considered for the development of novel therapies against different forms of scleroderma.
引用
收藏
页码:3813 / 3831
页数:19
相关论文
共 64 条
[1]
The Cannabinoid Receptor CB2 Exerts Antifibrotic Effects in Experimental Dermal Fibrosis [J].
Akhmetshina, Alfiya ;
Dees, Clara ;
Busch, Nicole ;
Beer, Juergen ;
Sarter, Kerstin ;
Zwerina, Jochen ;
Zimmer, Andreas ;
Distler, Oliver ;
Schett, Georg ;
Distler, Joerg H. W. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (04) :1129-1136
[2]
Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13882, 10.1111/bph.13877]
[3]
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors [J].
Alexander, Stephen P. H. ;
Cidlowski, John A. ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S208-S224
[4]
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors [J].
Alexander, Stephen P. H. ;
Christopoulos, Arthur ;
Davenport, Anthony P. ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S17-S129
[5]
Avouac J, 2014, METHODS MOL BIOL, V1142, P91, DOI 10.1007/978-1-4939-0404-4_11
[6]
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice [J].
Bae, Kwi-Hyun ;
Seo, Jung Beom ;
Jung, Yun-A ;
Seo, Hye-Young ;
Kang, Sun Hee ;
Jeon, Hui-Jeon ;
Lee, Jae Man ;
Lee, Sungwoo ;
Kim, Jung-Guk ;
Lee, In-Kyu ;
Jung, Gwon-Soo ;
Park, Keun-Gyu .
ENDOCRINOLOGY AND METABOLISM, 2017, 32 (01) :115-123
[7]
Baroni SS, 2006, NEW ENGL J MED, V354, P2667
[8]
Real-Time PyMOL Visualization for Rosetta and PyRosetta [J].
Baugh, Evan H. ;
Lyskov, Sergey ;
Weitzner, Brian D. ;
Gray, Jeffrey J. .
PLOS ONE, 2011, 6 (08)
[9]
Animal Models of Systemic Sclerosis Prospects and Limitations [J].
Beyer, Christian ;
Schett, Georg ;
Distler, Oliver ;
Distler, Joerg H. W. .
ARTHRITIS AND RHEUMATISM, 2010, 62 (10) :2831-2844
[10]
Effects of JWH015 in cytokine secretion in primary human keratinocytes and fibroblasts and its suitability for topical/transdermal delivery [J].
Bort, Alicia ;
Alvarado-Vazquez, Perla A. ;
Moracho-Vilrriales, Carolina ;
Virga, Kristopher G. ;
Gumina, Giuseppe ;
Romero-Sandoval, Alfonso ;
Asbill, Scott .
MOLECULAR PAIN, 2017, 13 :1-16